I am in this still hoping that Inspire 2.0 is a success similar to Inspire 1.0. Then after approval by the FDA the addition of stem cells and/or nerve growth factors could help patients even better perhaps.
Growing neural connections could have applications beyond spinal cord injury. Connecting computer interfaces to the brain may also use similar technology.
What surprises me is that there is so little interest in NVIV and so little hope for success. Early investors have been wiped out entirely. The latest investors are also bag holders. The CEO makes more than $1million per year.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.